Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 1833-1846

  White, Nicole M A ^a,b   Newsted, Daniel W ^a   Masui, Olena ^c   Romaschin, Alexander D ^b   Siu, K W Michael ^c   Yousef, George M ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c YORK UNIVERSITY   (Canada)

Author keywords

Bioinformatics; Citric acid cycle; Glucose metabolism; Metastasis; miRNA; Pathway analysis; Pentose phosphate pathway; Personalized medicine; Protein protein interactions; Proteomics; Renal cell carcinoma; Tumor markers

Indexed keywords

AMINO ACID METABOLISM; ARTICLE; BIOINFORMATICS; CHROMOSOME ABERRATION; CITRIC ACID CYCLE; GENE ONTOLOGY; GLYCOLYSIS; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; METABOLISM; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR GROWTH; VALIDATION STUDY;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASM METASTASIS; PROTEOMICS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84898924956     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1245-6     Document Type: Article

References (87)

1. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, et al. State of the science: an update on renal cell carcinoma. Mol Cancer Res. 2012;10:859-80.
2. Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol. 2010;7:327-38.
3. Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol. 2012;9:327-37.
4. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-24.
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-90.
6. Arsanious A, Bjarnason GA, Yousef GM. From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer. 2009;8:20.
7. Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, et al. Multi-level whole genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res. 2012;72:5273-84.
8. White NM, Yousef GM. Translating molecular signatures of renal cell carcinoma into clinical practice. J Urol. 2011;186:9-11.
9. Brannon AR, Rathmell WK. Renal cell carcinoma: where will the state-of-the-art lead us? Curr Oncol Rep. 2010;12:193-201.
10. Kaneko N, Gotoh A, Okamura N, Matsuo EI, Terao S, Watanabe M, et al. Potential tumor markers of renal cell carcinoma: α-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. Int J Urol. 2013;20(5):530-5.
11. Siu KW, DeSouza LV, Scorilas A, Romaschin AD, Honey RJ, Stewart R, et al. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res. 2009;8:3797-807.
12. Junker H, Venz S, Zimmermann U, Thiele A, Scharf C, Walther R. Stage-related alterations in renal cell carcinoma - comprehensive quantitative analysis by 2D-DIGE and protein network analysis. PLoS One. 2011;6:e21867.
13. Craven RA, Banks RE. Understanding and managing renal cell carcinoma: can proteomic studies contribute to clinical practice? Contrib Nephrol. 2008;160:88-106.
14. Romaschin AD, Youssef Y, Chow TF, Siu KW, DeSouza LV, Honey RJ, et al. Exploring the pathogenesis of renal cell carcinoma: pathway and bioinformatics analysis of dysregulated genes and proteins. Biol Chem. 2009;390:125-35.
15. Diamandis M, White NM, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res. 2010;8:1175-87.
16. Yousef GM. Personalized cancer genomics: the road map to clinical implementation. Clin Chem. 2012;58:661-3.
17. Masui O, White NMA, DeSouza LV, Krakovska O, Matta A, Metias S, et al. Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Proteomics. 2013;12:132-44.
18. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40:D109-14.
19. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011;39:D561-8.
20. Gronwald J, Storkel S, Holtgreve-Grez H, Hadaczek P, Brinkschmidt C, Jauch A, et al. Comparison of DNA gains and losses in primary renal clear cell carcinomas and metastatic sites: importance of 1q and 3p copy number changes in metastatic events. Cancer Res. 1997;57:481-7.
21. Wullich B, Riedinger S, Brinck U, Stoeckle M, Kamradt J, Ketter R, et al. Evidence for gains at 15q and 20q in brain metastases of prostate cancer. Cancer Genet Cytogenet. 2004;154:119-23.
22. Sayagues JM, Abad MM, Melchor HB, Gutierrez ML, Gonzalez-Gonzalez M, Jensen E, et al. Intratumoural cytogenetic heterogeneity of sporadic colorectal carcinomas suggests several pathways to liver metastasis. J Pathol. 2010;221:308-19.
23. Chen Y, Liou CP, Tseng HH, Jan YJ, Li CF, Tzeng CC. Deletions of chromosome 1p and 15q are associated with aggressiveness of gastrointestinal stromal tumors. J Formos Med Assoc. 2009;108:28-37.
24. Poetsch M, Woenckhaus C, Dittberner T, Pambor M, Lorenz G, Herrmann FH. Significance of the small subtelomeric area of chromosome 1 (1p36.3) in the progression of malignant melanoma: FISH deletion screening with YAC DNA probes. Virchows Arch. 1999;435:105-11.
25. Boelens MC, Kok K, van der Vlies P, van der Vries G, Sietsma H, Timens W, et al. Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer. 2009;66:372-8.
26. Petersen S, Aninat-Meyer M, Schluns K, Gellert K, Dietel M, Petersen I. Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer. 2000;82:65-73.
27. Friedrich K, Weber T, Scheithauer J, Meyer W, Haroske G, Kunze KD, et al. Chromosomal genotype in breast cancer progression: comparison of primary and secondary manifestations. Cell Oncol. 2008;30:39-50.
28. Li X, Chen J, Lu B, Peng S, Desper R, Lai M. 8p12-23 and +20q are predictors of subtypes and metastatic pathways in colorectal cancer: construction of tree models using comparative genomic hybridization data. OMICS. 2011;15:37-47.
29. Bockmuhl U, You X, Pacyna-Gengelbach M, Arps H, Draf W, Petersen I. CGH pattern of esthesioneuroblastoma and their metastases. Brain Pathol. 2004;14:158-63.
30. Alcock HE, Stephenson TJ, Royds JA, Hammond DW. Analysis of colorectal tumor progression by microdissection and comparative genomic hybridization. Genes Chromosomes Cancer. 2003;37:369-80.
31. Knosel T, Petersen S, Schwabe H, Schluns K, Stein U, Schlag PM, et al. Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch. 2002;440:187-94.
32. Maitra A, Molberg K, Albores-Saavedra J, Lindberg G. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol. 2000;157:1105-11.
33. Nakamura M, Ishida E, Shimada K, Kishi M, Nakase H, Sakaki T, et al. Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab Invest. 2005;85:165-75.
34. Shiraishi K, Okita K, Harada T, Kusano N, Furui T, Kondoh S, et al. Comparative genomic hybridization analysis of genetic aberrations associated with development and progression of biliary tract carcinomas. Cancer. 2001;91:570-7.
35. Gagos S, Hopwood VL, Iliopoulos D, Kostakis A, Karayannakos P, Yatzides H, et al. Chromosomal markers associated with metastasis in two colon cancer cell lines established from the same patient. Anticancer Res. 1995;15:369-78.
36. Goeze A, Schluns K, Wolf G, Thasler Z, Petersen S, Petersen I. Chromosomal imbalances of primary and metastatic lung adenocarcinomas. J Pathol. 2002;196:8-16.
37. Bockmuhl U, Schluns K, Schmidt S, Matthias S, Petersen I. Chromosomal alterations during metastasis formation of head and neck squamous cell carcinoma. Genes Chromosomes Cancer. 2002;33:29-35.
38. White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, et al. Yousef GM: miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer. 2011;105:1741-9.
39. Khella HW, White NM, Faragalla H, Gabril M, Boazak M, Dorian D, et al. Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses. Tumour Biol. 2012;33:131-40.
40. Pencheva N, Tran H, Buss C, Huh D, Drobnjak M, Busam K, et al. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell. 2012;151:1068-82.
41. Chen YR, Juan HF, Huang HC, Huang HH, Lee YJ, Liao MY, et al. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J Proteome Res. 2006;5:2727-42.
42. Chen YW, Chou HC, Lyu PC, Yin HS, Huang FL, Chang WS, et al. Mitochondrial proteomics analysis of tumorigenic and metastatic breast cancer markers. Funct Integr Genomics. 2011;11:225-39.
43. Vydra J, Selicharova I, Smutna K, Sanda M, Matouskova E, Bursikova E, et al. Two-dimensional electrophoretic comparison of metastatic and non-metastatic human breast tumors using in vitro cultured epithelial cells derived from the cancer tissues. BMC Cancer. 2008;8:107.
44. Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis. 2002;19:319-26.
45. Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol. 2007;20:1085-94.
46. Yao R, Davidson DD, Lopez-Beltran A, MacLennan GT, Montironi R, Cheng L. The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol. 2007;22:1025-32.
47. Xiao MB, Jiang F, Ni WK, Chen BY, Lu CH, Li XY, et al. High expression of S100A11 in pancreatic adenocarcinoma is an unfavorable prognostic marker. Med Oncol. 2012;29:1886-91.
48. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22:8031-41.
49. Wang WS, Chen PM, Hsiao HL, Ju SY, Su Y. Overexpression of the thymosin beta-4 gene is associated with malignant progression of SW480 colon cancer cells. Oncogene. 2003;22:3297-306.
50. Kim NS, Kang YJ, Jo JO, Kim HY, Oh YR, Kim YO, et al. Elevated expression of thymosin beta4, vascular endothelial growth factor (VEGF), and hypoxia inducible factor (HIF)-1alpha in early-stage cervical cancers. Pathol Oncol Res. 2011;17:493-502.
51. Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D, et al. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene. 2004;23:298-302.
52. Hagemann T, Bozanovic T, Hooper S, Ljubic A, Slettenaar VI, Wilson JL, et al. Molecular profiling of cervical cancer progression. Br J Cancer. 2007;96:321-8.
53. Conti A, Rodriguez GC, Chiechi A, Blazquez RM, Barbado V, Krenacs T, et al. Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis. Am J Pathol. 2011;178:88-97.
54. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519-30.
55. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7:277-85.
56. Wu CA, Chao Y, Shiah SG, Lin WW. Nutrient deprivation induces the Warburg effect through ROS/AMPK-dependent activation of pyruvate dehydrogenase kinase. Biochim Biophys Acta. 1833;2013:1147-56.
57. San MA, Ceballo S, Ruminot I, Lerchundi R, Frommer WB, Barros LF. A genetically encoded FRET lactate sensor and its use to detect the warburg effect in single cancer cells. PLoS One. 2013;8:e57712.
58. No authors listed (2013) AMPK can suppress tumorigenesis and the Warburg effect. Cancer Discov 3:OF15.
59. Buppajarntham S, Junpaparp P, Kue AP (2013) Warburg effect associated with transformed lymphoplasmacytic lymphoma to diffuse large B-cell lymphoma. Am J Emerg Med 1(6):999.e5-6
60. Poteet E, Choudhury GR, Winters A, Li W, Ryou MG, Liu R, et al. Reversing the Warburg effect as a treatment for glioblastoma. J Biol Chem. 2013;288(13):9153-64.
61. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51:349-53.
62. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000;60:916-21.
63. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891-9.
64. Glufosfamide: beta-D-Glc-IPM, D 19575. Drugs R D 2005;6(1):49-52.
65. Mazur L, Opydo-Chanek M, Stojak M. Glufosfamide as a new oxazaphosphorine anticancer agent. Anticancer Drugs. 2011;22:488-93.
66. Chiorean EG, Dragovich T, Hamm J, Langmuir VK, Kroll S, Jung DT, et al. A phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2008;61:1019-26.
67. Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, et al. A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer. 2009;45:1589-96.
68. Shimizu T, Okamoto I, Tamura K, Satoh T, Miyazaki M, Akashi Y, et al. Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors. Cancer Chemother Pharmacol. 2010;65:243-50.
69. Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, Reynolds GE, Chi JT, Wu J, Solow-Cordero DE, Bonnet M, Flanagan JU, Bouley DM, Graves EE, Denny WA, Hay MP, Giaccia AJ: Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011;3:94ra70.
70. Cao J, Cui S, Li S, Du C, Tian J, Wan S, et al. Targeted cancer therapy with a 2-deoxyglucose-based adriamycin complex. Cancer Res. 2013;73:1362-73.
71. Pollard PJ, Wortham NC, Tomlinson IP. The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Ann Med. 2003;35:632-9.
72. Denkert C, Budczies J, Weichert W, Wohlgemuth G, Scholz M, Kind T, et al. Metabolite profiling of human colon carcinoma - deregulation of TCA cycle and amino acid turnover. Mol Cancer. 2008;7:72.
73. Fernie AR, Carrari F, Sweetlove LJ. Respiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport. Curr Opin Plant Biol. 2004;7:254-61.
74. Jansen M, Mohapatra G, Betensky RA, Keohane C, Louis DN. Gain of chromosome arm 1q in atypical meningioma correlates with shorter progression-free survival. Neuropathol Appl Neurobiol. 2012;38:213-9.
75. Kilday JP, Mitra B, Domerg C, Ward J, Andreiuolo F, Osteso-Ibanez T, et al. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clin Cancer Res. 2012;18:2001-11.
76. Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM, et al. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer. 2009;125:2342-8.
77. Capurso G, Lattimore S, Crnogorac-Jurcevic T, Panzuto F, Milione M, Bhakta V, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer. 2006;13:541-58.
78. Kloth JN, Gorter A, Fleuren GJ, Oosting J, Uljee S, ter HN, et al. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol. 2008;215:222-30.
79. Carta F, Demuro PP, Zanini C, Santona A, Castiglia D, D'Atri S, et al. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res. 2005;15:235-44.
80. Shi W, Meng Z, Chen Z, Luo J, Liu L. Proteome analysis of human pancreatic cancer cell lines with highly liver metastatic potential by antibody microarray. Mol Cell Biochem. 2011;347:117-25.
81. An J, Sun JY, Yuan Q, Tian HY, Qiu WL, Guo W, et al. Proteomics analysis of differentially expressed metastasis-associated proteins in adenoid cystic carcinoma cell lines of human salivary gland. Oral Oncol. 2004;40:400-8.
82. Descotes F, Jezequel P, Spyratos F, Campion L, Grenot C, Lerebours F, et al. Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study. Int J Oncol. 2012;41:92-104.
83. Zhang H, Rakha EA, Ball GR, Spiteri I, Aleskandarany M, Paish EC, et al. The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Res Treat. 2010;121:41-51.
84. Kaloshi G, Mokhtari K, Carpentier C, Taillibert S, Lejeune J, Marie Y, et al. FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. J Neurooncol. 2007;84:245-8.
85. Teng Y, Ai Z, Wang Y, Wang J, Luo L. Proteomic identification of PKM2 and HSPA5 as potential biomarkers for predicting high-risk endometrial carcinoma. J Obstet Gynaecol Res. 2013;39:317-25.
86. Peng XC, Gong FM, Zhao YW, Zhou LX, Xie YW, Liao HL, et al. Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma. PLoS One. 2011;6:e27309.
87. Satoh Y, Mori K, Kitano K, Kitayama J, Yokota H, Sasaki H, et al. Analysis for the combination expression of CK20, FABP1 and MUC2 is sensitive for the prediction of peritoneal recurrence in gastric cancer. Jpn J Clin Oncol. 2012;42:148-52.